KINTOR PHARMA-B (09939) Announces February 2026 Monthly Return on Movements in Securities
Bulletin Express
Mar 04
KINTOR PHARMA-B (09939) released its Monthly Return for the period ended 28 February 2026. According to the announcement, the authorized share capital remained at 700.00 million ordinary shares (USD 0.0001 par value each), totaling 0.07 million USD in authorized capital, with no changes from the previous month.
The total number of issued shares stood at 498.66 million, with no treasury shares and no change compared to the preceding month. The company confirmed compliance with the applicable 25% public float requirement. There were no outstanding share options, warrants, convertibles, or other agreements to issue additional shares during the reporting period.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.